Related Experiment Videos
Pneumococcal septicaemia and meningitis in vaccinated splenectomized adult patients
1Department of Medicine and Hematology, Aarhus University Hospital, Amtssygehuset, Denmark.
Abstract:
A retrospective survey of the occurrence of pneumococcal septicaemia and meningitis in splenectomized adults was performed at a regional haematological centre after the introduction of pneumococcal vaccination in 1978. During this period 4 episodes of pneumococcal septicaemia were observed in 3 vaccinated, splenectomized patients. In all episodes the pathogenic strain was of an unusual serotype not included in the vaccine lending indirect evidence for the clinical efficacy of the pneumococcal vaccine, even in immunocompromised patients.
Insights
Pneumococcal vaccination shows efficacy in splenectomized adults, even those immunocompromised. Despite rare breakthrough cases, the vaccine protected against common serotypes, suggesting clinical benefit.
Area of Science:
- Infectious Diseases
- Immunology
- Vaccinology
Background:
- Splenectomized adults are at increased risk for severe pneumococcal infections.
- Pneumococcal vaccination was introduced in 1978 to mitigate this risk.
Observation:
- A retrospective study analyzed pneumococcal septicaemia and meningitis in vaccinated, splenectomized adults.
- Four episodes of pneumococcal septicaemia occurred in three patients during the study period.
Findings:
- All observed infections were caused by pneumococcal serotypes not covered by the vaccine.
- This suggests the vaccine was effective against vaccine-targeted serotypes in this high-risk group.
Implications:
- Pneumococcal vaccination offers clinical efficacy in immunocompromised patients, including splenectomized individuals.
- Further research into broader-spectrum pneumococcal vaccines is warranted for enhanced protection.